Home » Stocks » Genprex

Genprex, Inc. (GNPX)

Stock Price: $3.27 USD -0.12 (-3.54%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $3.29 +0.02 (0.61%) Oct 26, 7:29 PM

Stock Price Chart

Key Info

Market Cap 127.11M
Revenue (ttm) n/a
Net Income (ttm) -14.74M
Shares Out 38.87M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $3.27
Previous Close $3.39
Change ($) -0.12
Change (%) -3.54%
Day's Open 3.33
Day's Range 3.14 - 3.42
Day's Volume 651,159
52-Week Range 0.23 - 7.03

More Stats

Market Cap 127.11M
Enterprise Value 104.98M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.87M
Float 29.41M
EPS (basic) -0.60
EPS (diluted) -0.61
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.15M
Short Ratio 3.57
Short % of Float 10.69%
Beta -0.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.33
Revenue n/a
Operating Income -14.76M
Net Income -14.74M
Free Cash Flow -11.82M
Net Cash 22.13M
Net Cash / Share 0.57
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -59.50%
ROE -98.81%
ROIC -1,806.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $3.27
Target: 7.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-10.68-12.36-3.31-4.13-1.07
Net Income-10.65-12.37-3.31-4.13-1.07
Shares Outstanding16.0313.7711.5010.831.87
Earnings Per Share-0.66-0.90-0.29-0.38-0.57
Operating Cash Flow-6.92-6.85-2.17-1.25-0.69
Capital Expenditures-0.84-0.02-0.01--
Free Cash Flow-7.75-6.87-2.18-1.25-0.69
Cash & Equivalents2.008.600.161.600.24
Net Cash / Debt2.008.600.161.600.24
Book Value3.028.880.431.620.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Genprex, Inc.
Country United States
Employees 8
CEO J. Rodney Varner

Stock Information

Ticker Symbol GNPX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GNPX
IPO Date March 29, 2018


Genprex operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company's lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.